Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression
Yang S, Ling Y, Zhao F, Li W, Song Z, Wang L, Li Q, Liu M, Tong Y, Chen L, Ru D, Zhang T, Zhou K, Zhang B, Xu P, Yang Z, Li W, Song Y, Xu J, Zhu T, Shan F, Yu W, Lu H. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. Signal Transduction And Targeted Therapy 2022, 7: 91. PMID: 35304437, PMCID: PMC8931182, DOI: 10.1038/s41392-022-00952-w.Peer-Reviewed Original ResearchConceptsLesion absorptionCOVID-19 progressionTreat biliary spasmGround-glass opacitiesControl groupC-reactive proteinInhibitor of HA synthesisHyaluronic acidClinical COVID-19Levels of hyaluronanBiliary spasmClinical parametersD-dimerPulmonary lesionsTherapeutic effectPatientsSARS-CoV-2LymphocytesDrugCOVID-19HymecromoneHuman identical sequencesInhibitorsPrescription drugsHA synthesis